Filing Flows › Comparisons › IRD vs OVID
Opus Genetics vs Ovid Therapeutics: IRD and OVID compared
Opus Genetics is the larger company: $755K of revenue in its latest quarter (Q2 2026) against $733K for Ovid Therapeutics (Q2 2026). Opus Genetics is growing faster (-74% against -88% a year earlier).
Where the money goes: IRD and OVID
Opus Genetics (IRD) · Q2 2026
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Ovid Therapeutics (OVID) · Q2 2026
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
| Opus Genetics (IRD) | Ovid Therapeutics (OVID) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $755K | $733K |
| Revenue growth, Y/Y | -74% | -88% |
| Operating margin | n/m | n/m |
| Net earnings | −$8.1M | −$15.0M |
| Operating cash flow | −$11.9M | −$17.6M |
Questions
Which is bigger, Opus Genetics or Ovid Therapeutics?
Opus Genetics is the larger company: $755K of revenue in its latest quarter (Q2 2026) against $733K for Ovid Therapeutics (Q2 2026).
Is Opus Genetics or Ovid Therapeutics growing faster?
Opus Genetics is growing faster (-74% against -88% a year earlier).
More: Opus Genetics earnings · how Opus Genetics makes money · Ovid Therapeutics earnings · how Ovid Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.